Categories
All News

Auto Insurance Market: Global Industry Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2027

Market Expertz latest study, titled ‘Global Auto Insurance Market,’ sheds light on the crucial aspects of the global Auto Insurance market. The report aims to help readers accurately estimate the global market growth rate over the forecast period (2020-2027). Our market research team has meticulously performed quantitative and qualitative assessments of the Auto Insurance market dynamics, considering a slew of factors, including market penetration, product portfolios, end-user industries, pricing structure, and the key drivers, constraints, opportunities, and challenges predominantly affecting market growth.

The latest market study broadly segments the industry based on the product type range, application gamut, end-use industry, key regions, and the competitive background. One of the central components of the report is a detailed explanation of the gross profits, revenue shares, sales volume, manufacturing costs, individual growth rate, and the financial standing of the leading market players. The developmental scope of the Auto Insurance market’s new entrants and established companies has also been emphasized in the report.

Request a sample copy of the report to understand the structure of the complete [email protected] https://www.marketexpertz.com/sample-enquiry-form/23767

Competitive Terrain:

The global Auto Insurance market is highly consolidated due to the presence of numerous companies operating across this industry. The report depicts the current market standing of these companies, their past performances, demand and supply graphs, production and consumption patterns, sales network, distribution channels, and growth opportunities in the market. The leading market contenders listed in the report are:

Market segments by Top Manufacturers:

Allianz
USAA Property & Casualty
Amica Insurance
New Jersey Manufacturers Insurance Company
Erie Insurance Group
Auto Club Enterprises Insurance Group
Auto Club Insurance Association
Auto-Owners Insurance Group of Companies
Ameriprise Financial (IDS)
State Farm
State Auto Insurance Companies
Mercury
Geico

The latest report is inclusive of an extensive coverage of the significant impact of the COVID-19 pandemic on the Auto Insurance business sector. The coronavirus outbreak has drastically impacted the global economic landscape, and consequently, this particular business vertical. Therefore, the report provides the reader with a clear concept of the current scenario of this business vertical, estimating its COVID-19 aftereffects.

Get Your Copy at Discounted [email protected] https://www.marketexpertz.com/discount-enquiry-form/23767

Market segment by Type, the product can be split into
Liability Car Insurance
Physical Damage Car Insurance
Rental Insurance

Market segment by Application, Auto Insurance can be split into
Cars
Truck
SUVs

Geographical Scenario:

In this section of the report, market analysts have provided valuable insights into the geographical segmentation of the Auto Insurance market. They have further estimated the current and future market valuations on the basis of the demand-supply dynamics and pricing structure of the leading regional segments. Moreover, the growth prospects of each regional segment have been meticulously extensively discussed in the report.

The global Auto Insurance market is classified into the following regions:

  • North America (the U.S., Canada)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Europe (the U.K., Italy, Germany, France, Rest of EU)
  • Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • The Middle East & Africa (Saudi Arabia, the U.A.E., South Africa, Rest of MEA)

Browse the full report description, along with the ToCs and List of Facts and Figures @ https://www.marketexpertz.com/industry-overview/auto-insurance-market

Auto Insurance

Highlights of the Table of Contents:

  1. Report Overview

1.1 Research Scope

1.2 Key Auto Insurance market segments

1.3 Target players

1.4 Market analysis by type

1.5 Market analysis by application

1.6 Key learning objectives

1.7 Report timeline

  1. Global Growth Trends

2.1 Global Auto Insurance market size

2.2 Latest trends of the Auto Insurance market by region

2.3 Key corporate trends

  1. Auto Insurance Market shares of the key players

3.1 Global Auto Insurance size by manufacturers

3.2 Global Auto Insurance market key players

3.3 Products/solutions/services of major players

3.4 New entrants in the Auto Insurance market

3.5 Mergers, acquisitions, joint ventures, and expansion plans

  1. Auto Insurance Market by product segmentation

4.1 Global Auto Insurance Sales by Product

4.2 Global Auto Insurance by Product Revenue

Buy your copy [email protected] https://www.marketexpertz.com/checkout-form/23767

Thank you for reading our report. To find out more details on the report or to inquire about its customization, please contact us. We will offer you a report well-suited to your requirements.

Categories
All News News

The Market for Elastomeric Closures for Pharmaceutical Packaging is projected to grow to USD 9.3 Billion by 2030, claims Roots Analysis

Driven by the growing complexity of modern pharmacological interventions, industry stakeholders have turned to more versatile materials for the fabrication of compatible container closures; in this context, several elastomers have demonstrated significant potential

Roots Analysis has announced the addition of the Elastomeric Closure Components Market for Vials, Cartridges and Syringes, 2019-2030: Focus on Caps, Needle Shields, Plungers, Stoppers, Seals, Tip Caps and Other Closures” report to its list of offerings.

The materials used to fabricate pharmaceutical packaging components are extremely important in terms of preserving the stability, efficacy and safety of drug formulations. In fact, according to the USFDA, in the last two years, there have been over 2,000 drug and device recalls owing to packaging-related concerns. Elastomeric closures, with various types of coatings (such as FluoroTec® and Teflon®), have emerged as a promising option for pharmaceutical containers.

To order this 400+ page report, which features 185+ figures and 235+ tables, please visit this link

Key Market Insights 

Over 240 types of elastomeric closures are currently available
Presently, stoppers are the preferred closures, representing nearly 69% of all the products, followed by plungers (13%), caps / seals (7%) and tip caps / needle shields (7%). Popular stoppers include (in alphabetical order) NovaPure® Lyo Stopper, Omniflex3G®, PremiumCoat™, RayDyLyo® Cap, and Westar® RU Lyo Stopper.

Nearly 95% elastomeric closures are available in pre-sterilized format 
Commonly used sterilization techniques for such components include gamma irradiation, steam sterilization, and ethylene oxide; the use of such closures has been shown to save a significant amount of time by eliminating the need for multiple steps in the overall fill / finish process.

The market is highly fragmented; more than 80% of the products are manufactured by mid-sized and large manufacturers 
Over 47% of companies manufacturing elastomeric closures are mid-sized business entities (~50-500 employees), whereas 34% are large firms (>500 employees) and around 19% are small-sized players (<50 employees). Prominent examples of small and mid-sized companies engaged in this domain are (arranged in alphabetical order, established after 2004) Jiangyin AiSun Import & Export, JOTOP GLASS, Sonata Rubber, UD Pharma Rubber Products and Vighnesh Rubbers.

Over time, several partnerships have been established, focused on evaluating novel packaging materials 
Acquisitions and licensing agreements have been the most popular type of deals inked in this domain
The abovementioned deals represented over 40%, each, of the total number of instances reported in the period 2007-2019. Moreover, packaging containers / closures and affiliated technologies have emerged as primary focus areas for companies involved in such deals.

230+ drugs / therapies were approved in the past five years, of which over 35% are packaged using elastomeric closures
As more pharmacological products are approved and launched, the demand for container closures is anticipated to increase. Particularly, in terms of elastomeric materials, halobutyl rubber, butyl rubber, and polypropylene have emerged as popular fabrication materials.

In fact, the demand for elastomeric closures is expected to grow at an annualized rate of 5.3%
The current demand for elastomeric closures is estimated to be over 140 billion units and it is likely to grow to 250 billion units by 2030. Further, currently the Asia-Pacific region represents the highest share (48%) in terms of demand for elastomeric closures, compared to other regions.

Elastomeric closures for vials and cartridges, represent over 80% of the current market share
The major proportion of the market share (43%) in 2019 is expected to belong to closures intended for use in vials. By 2030, elastomeric closures for syringes are anticipated account for 19% of the market’s earnings; this can be attributed to the gradually increasing popularity of self-administration enabling drug delivery devices.

Automation and robot-assisted technologies are likely to be a key enabler within this domain
The role of robotics in pharmaceutical manufacturing and fill / finish operations is evolving; key players offering automation technologies and equipment for aseptic processing include (in decreasing order of number of proprietary robotic systems) Staubli, Seiko Epson, Marchesini Group, Massman Automation Designs and Tekpak.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • What are the popular types of elastomeric materials and coatings being used for the fabrication of closures for vials, ampoules and syringes?
  • What are the different types of drugs that require elastomeric closures?
  • How do parameters such as dosage form, route of administration and storage temperature of drugs, influence choice of elastomeric closures?
  • Who are the leading manufacturers of elastomeric closures across the globe?
  • What are the benefits of pre-sterilized closures? Who are the key players that offer pre-sterilized container-closure kits / systems?
  • What are the key drivers of partnership activity in this industry?
  • What are the key challenges associated with manufacturing of elastomeric components?
  • What is the current and future demand for parenteral containers and their respective closures?
  • What are the key factors that are likely to influence the evolution of the elastomeric closures market?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographies?

The USD 9.3 billion (by 2030) financial opportunity within elastomeric closures market has been analyzed across the following segments:

  • Type of packaging container
    • Vials
    • Syringes
    • Cartridges
  • Type of packaging closure
    • Seal
    • Stopper
    • Cap
    • Plunger
    • Barrel
    • Needle Shield
  • Sterilization status 
    • Pre-sterilized
    • Unsterilized
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom the anti-leaching property and limited interaction potential of elastomeric materials are some of the key reasons why such materials are preferred for fabrication of closures. The report includes detailed transcripts of discussions held with the following experts:

  • Julien Maréchal (Business Development and Technology Director, Aseptic Technologies)
  • Malcolm Gilmore (Facilitator, BioPhorum Operations Group)
  • Marco Pederiva (Marketing and Sales Director, Lonstroff)
  • Konstantin Kazarian (Project Manager of Business Development, PYRAMID Laboratories)

The research covers brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting the type of closure, container, composition and sterilization status. Each company profile includes recent developments related to elastomeric closures and parenteral packaging industry of the companies. 

  • Aptar Pharma
  • Daikyo Seiko
  • Datwyler Group
  • DWK Life Sciences
  • Hebei First Rubber Medical Technology (a Part of DESHENG Group)
  • Jiangsu Hualan New Pharmaceutical Material
  • Lonstroff (a Part of Sumitomo Rubber Industries)
  • Ompi (a Part of Stevanato Group)
  • West Pharmaceutical Services

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/elastomeric-closure-components-market-for-vials-cartridges-and-syringes-2019-2030-focus-on-caps-needle-shields-plungers-stoppers-seals-tip-caps-and-other-closures/255.html

or email [email protected]

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

Contract Manufacturing Services Market for vaccines is expected to grow at an annualized rate of over 10%, claims Roots Analysis

The steadily growing demand for vaccines, coupled to the discovery and development of a variety of both preventive and therapeutic vaccine products, has generated a range of new opportunities for contract manufacturers

Roots Analysis has announced the addition of the Vaccine Contract Manufacturing Market (2nd Edition), 2019- 2030 report to its list of offerings.

Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines. Having said that, numerous vaccine developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs); these service providers are consolidating their capabilities and are expanding their respective service portfolios through substantial acquisition activity.

To order this 400+ page report, which features 130+ figures and 125+ tables, please visit this link

Key Market Insights 

Over 90 companies, across the globe, presently claim to provide contract manufacturing services for vaccines 
The market landscape is fragmented featuring a mix of companies of all sizes. Majority of such service providers claim to use mammalian cell cultures for vaccine development and production. It is worth highlighting that over 60% of the CMOs are able to accommodate all scales of operation.

Partnership activity in this domain has increased at a CAGR of over 15%, since 2013
In fact, nearly 50% of the deals inked till date, were established post 2016. Majority of these agreements were observed to be focused on manufacturing various types of vaccines. Interestingly, stakeholders are mainly focused on manufacturing vaccines against infectious diseases, followed by oncology and respiratory diseases.

The demand for vaccines was estimated to be over 3 billion doses in 2018, and anticipated to increase
This is expected to be driven by public immunization initiatives and health programs. The report features a detailed forecast of the future demand for vaccines; this analysis is based on several relevant parameters, such as target patient population, dosing frequency, dose strength, type of vaccines and key geographies.

The installed vaccine manufacturing capacity is currently estimated to be over 1.2 million liters
The maximum share belongs to large (more than 1,000 employees) and very large (more than 5,000 employees) companies, representing more than 90% of the overall global capacity. In terms of location, the maximum vaccine manufacturing capacity is installed in Europe.

CMOs are actively investing in expanding existing capabilities to meet future requirements
The aim in this context is to acquire competencies across the supply chain, in order to cater to the evolving needs of clients / sponsors. Over 50 instances of facility expansions and new facility establishment were reported since 2013.

North America and Europe are anticipated to capture over 70% of the market share by 2030
Overall, the market is anticipated to witness an annualized growth rate of over 10% over the next decade. Contrary to North American and Europe, the market in the Asia Pacific region is anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • Who are the leading CMOs with expertise in vaccine production?
  • What are the preferred expression systems used in vaccine development and manufacturing?
  • What are the key challenges faced by vaccine manufacturers?
  • What the key CMOs across different regions that you can reach out to for your vaccine manufacturing requirements?
  • What are the clinical conditions for which vaccines are already available / under development?
  • What kind of partnership models (manufacturing agreements, licensing, process development, product development & commercialization, acquisitions, and others) are commonly adopted by industry stakeholders?
  • What is the annual commercial demand for vaccines?
  • How does the global vaccine manufacturing capacity compare to the total biopharmaceutical contract manufacturing capacity?
  • How much of vaccine manufacturing operations are outsourced to CMOs?
  • Which region presently makes the maximum contribution to the production of vaccines?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to vaccine contract manufacturing?

The financial opportunity of over USD 4 billion (by 2030) within the vaccine contract manufacturing market has been analyzed across the following segments:

  • Scale of Operation
    • Preclinical
    • Clinical
    • Commercial
  • Type of Expression System
    • Mammalian
    • Microbial
    • Others
  • Outsourced Business Operations
    • API Manufacturing
    • Fill / Finish
    • Others
  • Key geographical regions 
    • North America (US, Rest of North America)
    • Europe ((UK, France, Germany, Italy, Spain and rest of the Europe)
    • Asia-Pacific (India, China and Rest of Asia)
    • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom the current vaccine manufacturing revenues are primarily driven by various types of preventive vaccines; however, the scenario is likely to change in the future due to growing demand for therapeutic cancer vaccines. The report includes detailed transcripts of discussions held with the following experts:

  • Menzo Havenga, Chief Executive Officer, Batavia Biosciences and Claire Otjes, Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Ingrid Cromann, Director – Vaccine Development, Statens Serum Institut
  • Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
  • Oliver Schub, Senior Business Development Manager, ProBioGen
  • Sebastian Schuck, Head of Business Development, Wacker Biotech

The research covers detailed profiles of key players (illustrative list provided below) from across key global markets (North America, Europe and Asia-Pacific); each profile provides an overview of the company, information on its service portfolio, manufacturing facilities, financial performance (if available), details on recent developments, as well as an informed future outlook. 

  • Albany Molecular Research (AMRI)
  • Bharat Biotech
  • Biological E
  • BioReliance
  • Boehringer Ingelheim BioXcellence
  • Catalent Biologics
  • Charles River Laboratories
  • Cobra Biologics
  • Eurogentec
  • GreenPak Biotech
  • Hong Kong Institute of Biotechnology
  • IDT Biologika
  • Lonza
  • Meridian Life Science
  • WuXi Biologics

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/vaccine-contract-manufacturing-market-2nd-edition-2019-2030/262.html

or email [email protected]

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

Medical Device Contract Manufacturing Market is projected to reach USD 126 Billion by 2030, growing at an annualized rate of 8%, claims Roots Analysis

Owing to numerous technical and regulatory challenges related to the development and production of medical devices, outsourcing has become a popular business model for innovator companies; in fact, a number of contract manufacturing organizations (CMOs) presently provide specialized manufacturing services for various types of medical devices

Roots Analysis has announced the addition of Medical Device Contract Manufacturing Market, 2019-2030 report to its list of offerings.

More than 100 medical devices were approved by the FDA in 2018, while several are currently being evaluated across more than 9,500 (active) clinical trials, worldwide. Further, increase in aging population, coupled with rise in the prevalence of chronic disorders, are likely to drive the demand for medical devices. Therefore, in order to reduce the overall cost and expedite the time to market, majority of original equipment manufacturers (OEMs) are outsourcing their medical device manufacturing operations to CMOs.

To order this 550+ page report, which features 220+ figures and 220+ tables, please visit this link 

Key Market Insights 

Over 275 companies offer contract manufacturing services for finished medical device products 
The market is dominated by the presence of mid-sized companies (having 200 to 1,000 employees), which represent close to 53% of the competitive landscape. This is followed by small-sized companies (about 23%) and large firms (nearly 15%).

More than 60% of medical device CMOs are based in the US; majority of these CMOs have their manufacturing capabilities established within North America
Examples of such companies include (in alphabetical order, large and very large companies) Biomedical Innovations, Celestica, East West Manufacturing, Flex, Gerresheimer Jabil, Phillips-Medisize, Plexus Röchling Medical and Viant Medical. In fact, the US is presently considered a key hub for medical device contract manufacturing operations. Further, a significant number of players have also established their manufacturing facilities (more than 140) in Asia and other developing countries of the world.

Over 9,500+ clinical trials are evaluating a number of types of medical devices
Of these, around 60% trials are actively recruiting patients. So far, 4 million patients have been enrolled in ongoing / planned trials of medical devices. Interestingly, majority of these patients (more than 1.6 million) were enrolled in the Asia Pacific region, during the period between 2013 and 2019.

150+ mergers and acquisitions inked between 2014 and 2018 
The service portfolios of most of the acquired CMOs included medical device manufacturing services (more than 75%), design-related services (52%) and packaging services (14%). Examples of recent acquisitions in this domain include (in reverse chronological order) acquisition of Arcor Laser Services by Cadence (May 2019), ARCH Global Precision by The Jordan Company (April 2019) and Sparton by Cerberus Capital Management (March 2019). In terms of the device types, majority of the acquisitions were made for companies offering services for implants and instruments.

The market opportunity for medical device CMOs is likely to grow at an annualized rate of over 8% till 2030
Presently, medical device contract manufacturing services for cardiovascular disorders represent the dominant revenue generating segment (over 23%) in the overall market, followed by devices for oncological disorders (close to 12%) and CNS disorders (approximately 11%).

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • Who are the leading CMOs in the medical device contract manufacturing market?
  • Where are the medical device manufacturing facilities located?
  • What is the global, installed manufacturing capacity for medical devices?
  • What are the key value drivers behind the merger and acquisition activity in the medical device contract manufacturing industry?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the opportunities offered by emerging markets for medical device contract manufacturing?
  • What are the prevalent trends in medical device contract manufacturing?
  • What are the key challenges faced by medical device focused CMOs?
  • What is the role of automation in medical device manufacturing?
  • Is it possible to optimize the medical device supply chain to achieve cost benefits and ensure product quality?

The USD 126 billion (by 2030) financial opportunity within the medical device contract manufacturing market has been analyzed across the following segments:

  • Application areas
    • Therapeutic devices
    • Diagnostic devices
    • Drug delivery devices
    • Other devices
  • Device class
    • Class I medical devices
    • Class II medical devices
    • Class III medical devices
  • Therapeutic areas
    • Cardiovascular disorders
    • CNS disorders
    • Metabolic disorders
    • Oncological disorders
    • Orthopedic disorders
    • Ophthalmic disorders
    • Pain disorders
    • Respiratory disorders
    • Other therapeutic areas
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific
    • Rest of the world

The report also includes information on insights provided by the following industry experts:

  • Raghu Vadlamudi (Chief Research and Technology Director, Donatelle)
  • Jan Wahlström (President and Chief Executive Officer, Elos Medtech)

The research covers profiles of key players that offer contract manufacturing services for medical devices, featuring an overview of the company, its service portfolio, details on manufacturing facilities, and an informed future outlook. 

  • Cirtec Medical
  • Creganna Medical
  • DynaFlex Technologies
  • Europlaz Technologies
  • Interplex
  • I-Tek Medical Technologies
  • Keystone Solutions Group
  • Modern Medical
  • Oscor
  • Providence Enterprise
  • Riverside Medical Packaging
  • SMC
  • Stellartech
  • Suzhou Jenitek
  • Synecco
  • Trelleborg Sealing Solutions

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/medical-device-contract-manufacturing-market-2019-2030/258.html

or email [email protected]

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

Abuse Deterrent Formulation Technologies market is projected to grow at a healthy annualized rate of 16% till 2030, claims Roots Analysis

Advances in biotechnology and genome analysis have enabled the identification of several novel cancer biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, and to facilitate therapy related decisions

Roots Analysis has announced the addition of Abuse Deterrent Formulation Technologies Market, 2019-2030 report to its list of offerings.

Formulations that are capable of preventing an active pharmacological substance from being misused, offer a reliable way to limit the recreational / off-prescription drug use and its associated consequences. Several different types of abuse deterrent technologies have been developed in the last few years, which leverage either one or more of the following approaches to prevent abuse: physical / chemical barriers, agonist / antagonist combinations, aversive agents and prodrug format.

To order this 280+ page report, which features 65+ figures and 90+ tables, please visit this link 

Key Market Insights 

Close to 60 abuse deterrent formulation technologies are currently available / under development 
Nearly half of the technologies that we came across are based on the physical / chemical barriers approach; these are followed by the technologies that use agonist / antagonist combinations (11%) and prodrug approach (11%).

Opioids are presently the primary target drug class for abuse deterrent product development 
Over 75% of technology providers claim to be focused on developing tools to formulate safer and abuse proof versions of prescription pain medication. Other drug classes that represent likely candidates for tamper proofing include central nervous system (CNS) depressants and stimulants.

Over 8,000 patents have been filed / granted, since 2000
Of these, close to 5,000 patents related to abuse deterrent formulations and technologies were filed / granted in the US alone. Other key regions with significant intellectual capital include (in decreasing order of number of patents filed / granted) Australia, Europe, Canada, Mexico and China.

The partnership activity between drug and technology developers is anticipated to increase in the mid long term
Majority of the agreements (24%) established in the past were observed to have been focused on licensing and commercialization of abuse deterrent products. This was followed by agreements signed for the development of abuse deterrent formulations (22%), in the period 2013-2019 (till March).

North America and Europe are anticipated to capture over 95% of the market share by 2030
The abuse deterrent formulation technologies market is anticipated to witness rapid growth over the next decade. Further, the market for technologies targeting opioids is expected to capture the majority share in the coming years.

To request a sample copy / brochure of this report, please visit this link 

Key Questions Answered

  • What are the key drug classes that can be targeted for development of abuse deterrent formulations?
  • What are the most popular types of abuse deterrence approaches?
  • Who are the leading abuse deterrent technology providers in the market?
  • Which are the most popular abuse deterrent formulation technologies across players belonging to different peer groups?
  • What are the most popular types of partnership agreements in this domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the abuse deterrent formulation technologies market has been analyzed across the following segments:

  • Type of drug class 
    • Opioids
    • CNS Depressants
    • CNS Stimulants
  • Type of abuse deterrence approach
    • Physical / Chemical Barriers
    • Agonist / Antagonist Combinations
    • Aversion Approach
    • Prodrug Approach
    • Abuse Deterrent Drug Delivery Systems
  • Type of end product
    • Tablets
    • Capsules
    • Thin Films
    • Others
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific and Rest of the World

The report features inputs from eminent industry stakeholders, according to whom abuse deterrent formulation technologies are promising alternatives for addressing the concerns associated with prescription drug abuse, specifically opioids. The report includes detailed transcripts of discussions held with the following experts:

  • Greg Sturmer (President and Chief Executive Officer, Elysium Therapeutics)
  • Aia Malik (Commercial Development Manager, Healthcare, Lucideon)

Satta Result

The research covers brief profiles of several companies (including those listed below); each profile features an overview and key highlights of the company, financial information (if available), a description of its abuse deterrent formulation technology(s), and the recent developments and future outlook.

  • Acura Pharmaceuticals
  • Altus Formulation
  • BioDelivery Sciences International
  • CIMA LABS
  • Elysium Therapeutics
  • Grünenthal
  • Intellipharmaceutics
  • Purdue Pharma
  • TITAN Pharmaceuticals

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/abuse-deterrent-formulation-technologies-market-2019-2030/263.html

or email [email protected]

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

Global Novel Cell Sorting and Separation Market Size, Share, Revenue Analysis By Key Players, Market Size, Share, Key Developments, And Forecast 2030

Having demonstrated the ability to rapidly isolate rare cells from tissue samples and / or heterogenous cell populations, at minimal operational costs, novel cell isolation products and solutions have captured the interest of several stakeholders in the biopharmaceutical industry

Roots Analysis has announced the addition of the Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy-activated, Dielectrophoresis, Magnetophoretics, Microfluidics, Optoelectronics, Traceless Affinity and Other Technologies, 2019-2030 report to its list of offerings.

Over the years, extensive research in the field of flow cytometry has enabled the development of a variety of novel technologies that are capable of efficiently isolating rare cells from heterogenous cell populations. These innovative solutions are compatible for use across a myriad of application areas and coupled to the ongoing innovation in this domain, are likely to translate into lucrative future opportunity for stakeholders.

To order this 500+ page report, which features 290+ figures and 350+ tables, please visit this link

Key Market Insights 

More than 200+ innovative cell sorters, isolation kits and affiliated consumables currently available in the market
Cell sorters, based on innovative cell separation approaches and novel technologies, account for more than 45% of the total number of cell sorting products currently available in the market. Examples of innovative cell sorters include AcouTrap, C1™ System, Cytonome Viva™, LeviCell System, LumiSort™, Namo™ Single Cell Dispenser, Radiance™, Sefia S-1000, WOLF® Cell Sorter, and X-BACS™.

Microfluidics-based sorting technologies currently dominate the market, representing over 30% of novel cell isolation techniques 
Stakeholders claim that such products provide the most suitable micro-fabricated channels that actually allow for faster detection of single cells. Other advanced cell sorting principles include magnetophoretics, optoelectronics, buoyancy-activated, and acoustofluidics.

Currently, the major application areas of cell isolation technologies is genomic analysis and cancer diagnostics
More than 65% of the companies are presently developing products and solutions for use in genomics and transcriptomics-related applications. Further, around 30% of the companies have developed cell sorting solutions for use in cancer research, and diagnostic development.

3,000+ patents have been filed / granted since 2014
Since 2014, more than 500 patents have been filed / granted each year across the globe, with close to 850 patents in 2018, alone. It is worth highlighting that around 60% of the patents were filed / granted in the US.

Around 47% of published scientific articles were focused on the study of circulating tumor or fetal cells 
Several players in this filed are developing innovative products and solutions for isolating other cell types, such as blood cells, especially white and red blood cells; more than 50 articles that we came across were related to such efforts.

Close to USD 1 billion invested by both private and public investors, since 2014
Around USD 210 million was raised through venture capital financing, representing around 25% of the total capital raised in the given time period (till March 2019). Further, there were over 10 instances wherein firms have raised capital through IPOs / secondary offerings, accounting for more than USD 360 million in financing.

240+ partnerships established between 2014 and 2019 
This activity in this domain has increased at a CAGR of close to 40%. In fact, more than 75% such agreements have been signed since 2016, with the maximum reported in 2018. Majority of the aforementioned agreements were observed to be focused on R&D, or licensing of novel cell sorting products and solutions.

North America and Europe anticipated to capture over 80% of market share by 2030
Given the existing and anticipated demand across niche and emerging application areas, we expect the novel cell sorting products and solutions market to grow at an annualized rate of ~11% over the next decade. In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • What are the prevalent R&D trends related to cell sorting?
  • Who are the leading industry and non-industry players in this market?
  • What are the key challenges faced by novel cell sorting technology developers?
  • What kind of partnership models (research agreements, product / technology licensing, product development & commercialization, manufacturing agreements, acquisitions, clinical trial collaborations and others) are commonly adopted by industry stakeholders?
  • Who are the key investors in this field?
  • Who are the key thought leaders with expertise in cell sorting technologies?
  • What is the current and likely future demand for novel cell sorting products and solutions across key application areas?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the factors that are likely to influence the evolution of this upcoming market?

The financial opportunity within the novel cell sorting and separation market has been analyzed across the following segments:

  • Type of offering
    • Cell sorters
    • Consumables and isolation kits
  • Potential application area
    • Research studies
    • Circulating tumor cell detection
    • In vitro fertilization
    • Non-invasive prenatal diagnosis
    • Cell-based therapeutics
  • Cell sorting technology
    • Buoyancy-activated
    • Magnetophoretics
    • Microfluidics
    • Optoelectronics
    • Other advanced technologies
  • Type of cell
    • Animal cells
    • Cancer cells
    • Immune cells
    • Microbial cells
    • Red blood cells / platelets
    • Stem cells
  • Key geographical regions
    • North America
    • Europe
    • Asia Pacific

The report features inputs from eminent industry stakeholders, according to whom novel cell sorting products and solutions are expected to overcome the existing challenges associated with conventional cell separation techniques. The report includes detailed transcripts of discussions held with the following experts:

  • John Younger (Co-Founder and Chief Technology Officer, Akadeum Life Sciences)
  • Sean Hart (Chief Executive Officer and Chief Scientific Officer, LumaCyte)
  • Soohee Cho (Product Manager, Namocell)

The research covers elaborate profiles, featuring an overview of the company, its financial information (if available), and a detailed description of its proprietary product(s). Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future

  • Akadeum Life Sciences
  • Cesca Therapeutics
  • Cytonome
  • Fluidigm
  • Innovative Biochips
  • LevitasBio
  • LumaCyte
  • Namocell
  • NanoCellect Biomedical
  • QIAGEN
  • RareCyte®
  • ScreenCell
  • STEMCELL Technologies
  • Union Biometrica

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/novel-cell-sorting-and-separation-market-focus-on-acoustophoresis-buoyancy-dielectrophoresis-magnetophoretics-microfluidics-optoelectronics-traceless-affinity-and-other-technologies-2019-2030/266.html

or email [email protected]

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

CAR-T Therapies Market is projected to reach USD 11 Billion by 2030, growing at an annualized rate of 31%, claims Roots Analysis

Given the recent success of KYMRIAH® and YESCARTA®, the current focus is on establishing a sustainable chimeric antigen receptor T (CAR-T) cell therapy market, ensuing that such interventions are not only safe and effective, but also affordable

Roots Analysis has announced the addition of CAR-T Therapies Market (2nd Edition), 2019-2030 report to its list of offerings.

Encouraging clinical results reported across several completed and ongoing trials, coupled to lucrative financing, have inspired many biopharmaceutical developers and academic research groups to focus their efforts on this relatively novel class of immunotherapies. With two approved products, CAR-T cell therapies are presently considered among the most promising therapeutic interventions available. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 580+ page report, which features 130+ figures and 270+ tables, please visit this link 

Key Market Insights 

Close to 500 CAR-T cell therapy candidates are in the development pipeline
Over 100 companies and 85 academic / research institutes are actively involved in this domain. It is worth highlighting that 66% of the pipeline therapies are presently in the clinical stage. Examples of late-stage clinical candidates include bb2121 (bluebird bio / Celegene), JCAR017 (Celgene / Juno Therapeutics / WuXi AppTec), EPCAM CAR-T (Sinobioway Cell Therapy), MB-CART19.1 (Miltenyi Biotec / Shanghai Children’s Medical Center) and LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen).

Currently, the focus is on hematological malignancies and solid tumor indications 
More than 95% of the products in the pipeline are being developed to treat various types of cancers, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, multiple myeloma and chronic lymphocytic leukemia. Only 2% of such therapies are being evaluated for the treatment of non-oncological indications.

Extensive efforts are underway to improve CAR constructs
Majority of the CAR-T cell therapies in the clinical pipeline, including the two approved drug products, are based on second generation CARs. Therapy candidates based on the fourth generation of CARs are under development, currently representing 15% of the overall pipeline.

China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
In the last 10 years, over 410 clinical trials, evaluating various types of CAR-T cell therapies, were registered across different geographies; interestingly, over 50% of these trials are being conducted in China.

North America and Europe anticipated to capture over 75% of the market share by 2030
North America and Europe are the current hubs of R&D and sales activity and are likely to continue to dominate the market over the next decade. However, owing to the fact that more than 60% of the CAR-T trials are currently being conducted in China, this market is likely to grow at a relatively faster rate, compared to developed regions.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • Who are the leading industry and non-industry players in this market?
  • What kind of clinical conditions can be treated using CAR-T cell therapies?
  • What are the prevalent R&D trends related to CAR-T cell therapies?
  • Which are the key / emerging CMOs, in different regions, that you can reach out to for your CAR-T cell therapy manufacturing requirements?
  • Who are the key opinion leaders / experts in this field, who can help drive your CAR-T cell therapy development efforts?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the key factors that are likely to influence the evolution of the CAR-T cell therapy market?
  • What are the key promotional strategies that are likely to be adopted for CAR-T cell therapy products that are approved and commercialized in the near future?
  • What are the key challenges faced by CAR-T cell therapy developers?

The USD 11 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

  • Disease indication
    • Acute lymphoblastic leukemia
    • Multiple myeloma
    • Chronic lymphocytic leukemia
    • Non-Hodgkin lymphoma
    • Hepatocellular carcinoma
    • Colorectal cancer
  • Target antigens
    • CD19
    • BCMA
    • GPC3
    • EGFR
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific

The report features inputs from eminent industry stakeholders, according to whom T-cell immunotherapies are expected to be the next big thing in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

The research covers brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. 

  • Autolus
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene
  • Cell Medica
  • Cellectis
  • Cellular Biomedicine Group
  • Innovative Cellular Therapeutics
  • Kite Pharma
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Ziopharm Oncology

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market-2nd-edition-2019-2030/269.html

or email [email protected]

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

Viral and Non-Viral Vector Manufacturing Market is anticipated to grow at an annualized rate of over 20%, claims Roots Analysis

The recent surge in interest in genetically-modified therapies has resulted in a steep rise in demand for different vectors for fundamental and pharmacological research, opening up opportunities for companies with expertise in targeted gene delivery

Roots Analysis has announced the addition of Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors) report to its list of offerings.

Currently, biopharmaceutical developers are plagued by high development costs, complex production protocols and the need for specialized equipment, in order to ensure the safety and quality of complex biological interventions, such as cell and gene therapies. Consequently, a number of innovator companies have demonstrated a preference for outsourcing vector manufacturing, a key aspect of advanced, genetically-modified product development, to contract service providers.

To order this 430+ page report, which features 140+ figures and 180+ tables, please visit this link

Key Market Insights 

The market is fragmented, with over 180 industry players and non-industry players
Over 50% of industry players are large or mid-sized firms. In recent years, the growing demand for vectors has spurred the establishment of several start-ups, as well. Further, more than 80 non-industry players, including universities, research institutes and hospitals, are also currently involved in producing viral vectors or plasmid DNA for use in genetically modified therapies

The demand for vectors for research / clinical use is presently more than that for commercial applications
Approximately 80% of industry stakeholders presently claim to manufacture vectors at the laboratory and / or clinical scale. However, some firms (around 40, as per our research) have developed / are developing commercial scale capacity for the production of viral vectors or plasmid DNA.

The US and EU have emerged as major vector manufacturing hubs
High volume of active clinical studies, requiring vectors, being conducted in these regions makes the US and EU the major vector manufacturing hubs. Approximately 50% of the vector manufacturing facilities are located in North America. This is followed by the EU, where approximately 45% of the world’s vector manufacturing facilities are located.

The current installed vector manufacturing capacity in the world is estimated to be over 60,000 L 
The major share (70%) of the global vector manufacturing capacity belongs to companies that are manufacturing vectors at both clinical and commercial scales. Across the major global regions, 50% of the total installed vector manufacturing capacity is in the US. This can be attributed to the large number of small-sized and mid-sized companies that are presently situated in this region.

Around 140 partnerships were inked during the last three years
The maximum number of deals (37) were reported in 2016, followed by 27 partnerships established in 2018. Around 30% of the deals were related to the manufacturing of vectors across different scales of operation; this was followed by technology licensing agreements (23%).

90% of the market share is captured by viral vectors intended for use in oncological disorders 
Driven by the rapidly evolving pipeline of genetically modified therapies, including T-cell therapies and vector-based vaccines, and the increasing adoption of advanced production technologies, the vector manufacturing market is projected to grow at an accelerated pace. Specifically, revenues generated from the sales of lentiviral vectors currently represent the largest share of the market, followed by retroviral vectors.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • What are the various types of vectors being used for the production of cell and gene therapies?
  • Who are the leading industry and non-industry players in this market?
  • What is the trend of outsourcing in the vector manufacturing domain?
  • What are the key technical advances / innovations in vector manufacturing?
  • What are the trends in partnership and licensing activity in this domain?
  • What is the installed vector manufacturing capacity across key global geographies?
  • What is the current and future demand for viral and non-viral vectors?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Close to USD 2 billion (by 2030) financial opportunity within the vector manufacturing market has been analyzed across the following segments:

  • Type of Vector
    • AAV
    • Adenoviral
    • Lentiviral
    • Retroviral
    • Plasmid DNA
    • Other Vectors
  • Application
    • Gene Therapy
    • T-Cell Therapy
    • Vaccines
  • Therapeutic Area
    • Oncological Disorders
    • Inflammation & Immunological Disorders
    • Neurological Disorders
    • Ophthalmological Disorders
    • Muscle Disorders
    • Metabolic Disorders
    • Cardiovascular Disorders
    • Others
  • Scale of Operation
    • Preclinical
    • Clinical
    • Commercial
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom there is an evident need for industry stakeholders to modify operational models and expand manufacturing capabilities in order to ensure uninterrupted growth within the market. The report includes detailed transcripts of discussions held with the following experts:

  • Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
  • Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Olivier Boisteau, (President / Co-Founder, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
  • Joost van den Berg (Director, Amsterdam BioTherapeutics Unit)
  • Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
  • Colin Lee Novick (Managing Director, CJ Partners)
  • Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)
  • Semyon Rubinchik (Scientific Director, ACGT)
  • Alain Lamproye (President of Biopharma Business Unit, Novasep)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)
  • Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)

The research covers brief profiles of several companies (including those listed below); each profile features an overview of the company, financial information (if available), vector manufacturing technology, manufacturing facilities, vector manufacturing experience and an informed future outlook of the company.

  • Aldevron
  • BioReliance (a part of SAFC Commercial)
  • Biovian
  • bluebird bio
  • Brammer Bio
  • Cell and Gene Therapy Catapult
  • Cobra Biologics
  • FinVector
  • FUJIFILM Diosynth Biotechnologies
  • Kaneka Eurogentec
  • Lonza
  • MassBiologics
  • MolMed
  • Novasep
  • Oxford BioMedica
  • Richter-Helm
  • Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
  • Spark Therapeutics
  • uniQure
  • Vigene Biosciences
  • VIVEbiotech
  • WuXi AppTec

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-3rd-edition-2019-2030-focus-on-aav-adenoviral-lentiviral-retroviral-plasmid-dna-and-other-vectors/274.html or email [email protected] 

You may also be interested in the following titles: 

  1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
  2. Gene Therapy Market (3rd Edition), 2019 – 2030
  3. Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030
  4. Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

Antibody Drug Conjugates Market is projected to be worth more than USD 15 Billion by 2030, growing at a CAGR of over 20%, claims Roots Analysis

The growing popularity and therapeutic potential of antibody drug conjugates (ADCs) is evident in the rapid growth in intellectual capital, financing and partnership activity reported in the past five years

Roots Analysis has announced the addition of Antibody Drug Conjugates Market (5th Edition), 2019-2030 report to its list of offerings.

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link 

Key Market Insights 

Around 250 ADCs are currently under development  
Of these, nearly 40% are in the clinical phase of development, while the rest are in the preclinical / discovery stage. Presently, most of such therapeutic leads are being developed against the HER2 antigen; other popular biological targets include CD30 and EGFR.

60% of clinical stage therapy candidates are designed for the treatment of solid tumors
Within this segment, breast cancer (which represents a share of 22%) is currently the most popular target indication (in terms of number of therapy candidates in the pipeline), followed by non-small cell lung cancer (10%). ADC therapeutics are also being developed for hematological malignancies, such as multiple myeloma (31%), lymphoma (27%) and leukemia (27%).

More than 11,000 patents have been filed / granted related to ADCs and affiliated technologies, since 2015
Around 40% of these intellectual property documents were filed / granted in the US; other key regions with significant intellectual capital include China, Japan, Canada, Korea and Taiwan. Leading non industry players (in terms of the size of intellectual property portfolio) include INSERM, University of California, Leland Stanford Junior University and University of Pennsylvania.

USD 5+ billion has been invested by both private and public investors, till 2019
Around USD 2 billion was raised through venture capital financing alone, representing 40% of the total capital amount raised since 2011. Further, there have been six IPOs, from which companies claim to have raised over USD 1 billion in financing.

Partnership activity in this field has increased at an annualized rate of 30%    
In fact, around 60% of the deals considered in this analysis were established post 2015, the maximum activity being reported in 2018. Majority of these agreements (over 100) were observed to be either R&D agreements and / or licensing deals.

Over time, CMOs have become indispensable to the R&D and manufacturing activity in this domain  
Presently, 30 CMOs have the required capabilities to manufacture and conjugate ADCs; of these, 50% claim to be one-stop-shops, providing end-to-end services across all steps of ADC manufacturing. Further, over 80% of ADC contract manufacturers are based in either North America or Europe with facilities dedicated to ADC manufacturing / conjugation located in one or multiple regions.

North America and Europe are anticipated to capture over 80% of the market share by 2030
It also worth noting that ADC products using VC linkers and SMCC linkers are likely to capture more than 60% of the market. Further, based on type of cytotoxic payload, ADCs using MMAE and DMI are anticipated to capture close to 50% of the overall market share.

To request a sample copy / brochure of this report, please visit this link    

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in this market?
  • Who are the key ADC development and manufacturing technology providers?
  • What are the prevalent and upcoming trends related to ADC payload and linkers?
  • What are the new biologic target antigens being explored for ADC development?
  • Who are the key / emerging CMOs, in different regions, that you can reach out to for your manufacturing requirements?
  • Who are the key investors in the ADC market?
  • What are the most prominent drugs / therapies being currently used in combination with ADCs?
  • What kind of partnership models are commonly adopted by ADC developers / manufacturers?
  • Who are the key opinion leaders / experts who can support contemporary ADC development efforts?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What kind of commercialization and promotional strategies are being used by ADC developers?

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:

  • Type of Payload
    • MMAE
    • DM4
    • Camptothecin
    • DM1
    • MMAF
    • Others
  • Type of Linker
    • VC
    • Sulfo-SPDB
    • SMCC
    • VA
    • Hydrazone
    • Others
  • Target Indication
    • Breast cancer
    • Lymphoma
    • Leukemia
    • Urothelial cancer
    • Lung cancer
    • Ovarian cancer
    • Others
  • Target Antigen
    • CD30
    • HER2
    • CD22
    • CD33
    • Others
  • Technology Providers
    • Seattle Genetics
    • ImmunoGen
    • StemCentRx
    • Immunomedics
    • Others
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia Pacific

The report features inputs from eminent industry stakeholders, according to whom upcoming generations of ADC therapeutics are likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts:

  • Alan Burnett (Professor, School of Medicine, Cardiff University)
  • Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • John Burt (Chief Executive Officer, Abzena)
  • Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)Satta King online Result
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
  • Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)
  • Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)

The research covers elaborate profiles, featuring an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook. 

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Daiichi Sankyo
  • Pfizer
  • Roche / Genentech
  • Synthon
  • Bayer HealthCare
  • Biotest Pharmaceuticals

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

or email [email protected] 

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]

Categories
All News News

Large Volume Wearable Injectors Market is anticipated to grow at a CAGR of 40%, claims Roots Analysis

The shift to self-administration of medication, coupled to the need to improve therapy adherence, have driven device developers to design versatile drug delivery devices capable of minimizing dosing-related errors and preventing needlestick injuries

Roots Analysis has announced the addition of Large Volume Wearable Injectors Market (4th Edition), 2018-2030 report to its list of offerings.

Over time, both drug developers and medical device manufacturers, have entered into strategic alliances to combine their respective expertise and develop appropriate drug-device combination products. Presently, multiple such combinations, facilitating easy delivery of both insulin and non-insulin drugs, in large volumes, are either already available in the market or under development.

To order this 350+ page report, which features 105+ figures and 130+ tables, please visit this link 

Key Market Insights 

Close to 50 large volume wearable injectors are available / under development 
Around 17% of such devices have been designed to hold 10-15 ml of drug formulation, while 23% claim to have the capacity to hold more than 15 ml. Concerning type of dosing, 40% of these devices are developed / being developed for bolus dosing, and 40% for continuous dosing, the remaining (20%) devices are capable of facilitating both types of doses.

At present, there are 80+ biologics / small molecules that are most likely to be developed as drug-device combination products 
The report provides insights on over 600+ marketed drugs / therapies and pipeline candidates, assessing the likelihood of whether they may be developed in combination with large volume wearable injectors or not. The analysis takes into consideration stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs).

Close to 2,000 patents pertaining to large volume wearable injectors have been filed / granted till 2018
Most of the intellectual property documents in this field were observed to be associated with personal health monitoring systems, electronic patient care, needle retraction systems and smartphone-based drug delivery systems and solutions.

Outsourcing has emerged as a popular strategy for manufacturing device-related components
The development process of high-volume drug injection devices is complex, characterized by the need for multiple components (electrical and mechanical modules) and multidisciplinary technical experience. It is worth highlighting that close to 50% of the total number of CMOs involved in providing services for such injectors, are based in North America.

Several clinical trials, evaluating drug-device combinations, were initiated between 2016 and 2018
Close to 60% of such trials are presently in the early (Phase I and Phase II) stages. The report features an in-depth analysis of clinical research initiatives in this field based on relevant parameters, such as trial registration year, current trial status, phase of development, and study design.

North America and Europe are anticipated to capture over 60% of the overall market share by 2030
Presently, only patch injectors are available in the market, therefore, they are the sole contributors to the current market size. However, by 2030, 19% of the overall market share is expected to be captured by infusion pumps.

To request a sample copy / brochure of this report, please visit this link 

Key Questions Answered

  • How is the current and future market opportunity likely to be distributed across key market segments?
  • Who are the leading drug delivery device manufacturers in this market?
  • How do modern large volume, wearable injector devices compare to each other (in terms of key specifications and strengths of manufacturer companies)?
  • What are the prevalent R&D trends related to large volume wearable injectors (in terms of clinical research activity, and number of patents)?
  • What is the role of contract manufacturing organizations in the supply chain of large volume wearable injectors?
  • What are the recent developments and enabling technologies that are likely to influence the future of the large volume wearable injectors market?

The USD 650 million (by 2030) financial opportunity within the large volume wearable injectors market has been analyzed across the following segments:

  • Type of device
    • Patch Pumps / Injectors
    • Infusion Pumps / Injectors
  • Usability
    • Disposable
    • Reusable
  • Therapeutic Area 
    • Neurological Disorders
    • Oncological Disorders
    • Cardiovascular Disorders
    • Pain Management
    • Infectious Diseases
  • Key geographical regions 
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom the market is likely to be driven drug-device combinations of biologics (with the appropriate delivery devices), which are generally required to be administered in large volumes. Moreover, developers are attempting to gain a competitive edge by including certain distinguishing features, such as integrated mobile applications with smart health monitoring, provisions for audiovisual notifications, automatic drug reconstitution and error alerts, in their proprietary products. The report includes detailed transcripts of discussions held with the following experts:

Satta King Result

  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
  • Mike Hooven (President and Chief Executive Officer, Enable Injections)
  • Mark Banister (Chief Executive Officer, Medipacs)
  • Pieter Muntendam (President and Chief Executive Officer, scPharmaceuticals)
  • Mindy Katz (Director of Product, Sorrel Medical)
  • Jesper Roested (Chief Executive Officer, Subcuject)
  • Graham Reynolds (Vice President & General Manager, Global Biologics, West Pharmaceutical Services)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services)

The research includes detailed profiles, featuring an overview of the company, its financial information (if available), and a description of the product(s) offered. Each company profile includes recent developments related to large volume wearable injectors and an informed opinion on the likely strategies that may be adopted by these players to fuel growth in the foreseen future. 

  • Becton Dickinson
  • Bespak
  • Cellnovo
  • CeQur
  • Debiotech
  • Eli Lilly
  • Enable Injections
  • Insulet
  • Medtronic
  • PharmaSens
  • Roche
  • SOOIL Development
  • Sonceboz
  • Sensile Medical
  • SteadyMed Therapeutics
  • Tandem Diabetes Care
  • Weibel CDS
  • West Pharmaceutical Services

For additional details, please visit 
https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

or email [email protected]

Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]